FIGURE 1.
Main potential targets for drug design in AD and relation of its pathways. (A) AD’s targets used to develop new drugs in clinical trials evaluated in this work. (B) All mechanisms related to AD pathogenesis and progression are connected and were explored in these clinical trials, such as Aβ and tau aggregation; BACE-1, γ-secretase, or glutaminyl cyclase activity; neuroinflammation; excitotoxicity; 5-HT7R or 5-HT6R hyperstimulation and cholinergic impairment.